PURPOSE: Antipsychotic efficacy in schizophrenia depends on its availability in the body. Although therapeutic outcomes remain still far from satisfactory, therapeutic drug monitoring is not a common part of clinical practice during treatment with long-acting injectable antipsychotics (LAI AP). The real effectiveness of LAI AP is thus uncertain. PATIENTS AND METHODS: We made a retrospective evaluation of plasma levels of LAI AP. Collection of blood samples was performed just before the drug application and one week later. Forty patients with a stabilized clinical condition and steady-state plasma levels were included. RESULTS: In the observed cohort of patients, flupentixol decanoate (n = 23) was the most often used drug, followed by fluphenazine decanoate (n = 7), haloperidol decanoate (n = 5), paliperidone palmitate (n = 3), and risperidone microspheres (n = 2). Just 5 of 40 patients were treated with a monotherapy. In the period before the application, 60% of the patients did not reach the therapeutic reference range (TRR) and 20% of the patients had an undetectable plasma level. At the time of collection of the second blood samples performed after 7 days, 24% of the patients were under the TRR. CONCLUSION: We have found a surprisingly high incidence of plasma levels under the TRR in patients treated with LAI AP. Notwithstanding individual variability in pharmacokinetics, it seems that LAI AP may be underdosed in usual clinical practice.

Department of Clinical Neurosciences Faculty of Medicine University of Ostrava Ostrava Czech Republic

Department of Clinical Pharmacology Faculty of Medicine University of Ostrava Ostrava Czech Republic

Department of Clinical Pharmacology Institute of Laboratory Diagnostics University Hospital Ostrava Ostrava Czech Republic

Department of Psychiatry University Hospital Ostrava Ostrava Czech Republic

See more in PubMed

Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1–2):9–62. doi:10.1055/s-0043-116492 PubMed DOI

Mac Ewan JP, Kamat SA, Duffy RA, et al. Hospital readmission rates among patients with schizophrenia treated with long-acting injectables or oral antipsychotics. Psychiatr Serv. 2016;67(11):1183–1188. doi:10.1176/appi.ps.201500455 PubMed DOI

Poloni N, Ielmini M, Caselli I, et al. Oral antipsychotic versus long-acting injections antipsychotic in schizophrenia spectrum disorder: a mirror analysis in a real-world clinical setting. Psychopharmacol Bull. 2019;49(2):17–27. PubMed PMC

Ostuzzi G, Bighelli I, So R, Furukawa TA, Barbui C. Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. Schizophr Res. 2017;183:10–21. doi:10.1016/j.schres.2016.11.010 PubMed DOI

Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry. 2003;64(Suppl 16):18–23. PubMed

Ostuzzi G, Mazzi MA, Terlizzi S, et al. Factors associated with first- versus second- generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy. PLoS One. 2018;13(8):e0201371. doi:10.1371/journal.pone.0201371 PubMed DOI PMC

Bartoli F, Ostuzzi G, Crocamo C, et al. Clinical correlates of paliperidone palmitate and aripiprazole monohydrate prescription for subjects with schizophrenia-spectrum disorders: findings from the STAR Network Depot Study. Int Clin Psychopharmacol. 2020;35(4):214–220. doi:10.1097/YIC.0000000000000317 PubMed DOI

World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Description and Diagnostic Guidelines. Geneva: World Health Organization; 1992.

Urinovska R, Brozmanova H, Sistik P, et al. Liquid chromatography–tandem mass spectrometry method for determination of five antidepressants and four atypical antipsychotics and their main metabolites in human serum. J Chromatogr B. 2012;907:101–107. doi:10.1016/j.jchromb.2012.09.009 PubMed DOI

McCutcheon R, Beck K, D´Ambrosio E, et al. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand. 2018;137(1):39–46. doi:10.1111/acps.12825 PubMed DOI PMC

Barnes TR, Shingleton-Smith A, Paton C. Antipsychotic long-acting injections: prescribing practice in the UK. Br J Psychiatry Suppl. 2009;52(S52):S37–42. doi:10.1192/bjp.195.52.s37 PubMed DOI

Marder SR, Aravagiri M, Wirshing WC, Wirshing DA, Lebell M, Mintz J. Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate. Schizophr Res. 2002;53(1–2):25–30. doi:10.1016/S0920-9964(00)00184-5 PubMed DOI

Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo E. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs. 2003;63(5):493–612. doi:10.2165/00003495-200363050-00004 PubMed DOI

Harrow M, Jobe TH, Faull RN. Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. Psychol Med. 2014;44(14):3007–3016. doi:10.1017/S0033291714000610 PubMed DOI

Cordiner M, Shajahan P, McAvoy S, Bashir M, Taylor M. Effectiveness of long-acting antipsychotics in clinical practice: 2. Effects of antipsychotic polypharmacy on risperidone long-acting injection and zuclopenthixol decanoate. Ther Adv Psychopharmacol. 2016;6(2):66–76. doi:10.1177/2045125315623584 PubMed DOI PMC

Correll CU, Gallego JA. Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatr Clin North Am. 2012;35(3):661–681. doi:10.1016/j.psc.2012.06.007 PubMed DOI PMC